Simplifying Global Compliance
Two Biosimilar Guidances on FDA’s 2013 Agenda But No Interchangeability
The FDA plans to release two guidances to assist biosimilar sponsors this year, but drugmakers hoping for advice on how to achieve the coveted interchangeable designation shouldn’t get their hopes up.
To View This Article:
Subscribe To Generic Line
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing